NanoViricides, Inc. (NYSE:NNVC – Get Free Report) shares were down 1.8% on Wednesday . The company traded as low as $1.05 and last traded at $1.08. Approximately 189,999 shares traded hands during trading, a decline of 60% from the average daily volume of 473,750 shares. The stock had previously closed at $1.10.
Analyst Ratings Changes
Separately, StockNews.com downgraded NanoViricides from a “hold” rating to a “sell” rating in a research note on Monday, November 18th.
Get Our Latest Report on NanoViricides
NanoViricides Price Performance
Hedge Funds Weigh In On NanoViricides
An institutional investor recently raised its position in NanoViricides stock. Integrated Wealth Concepts LLC boosted its stake in shares of NanoViricides, Inc. (NYSE:NNVC – Free Report) by 44.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 53,335 shares of the company’s stock after purchasing an additional 16,500 shares during the period. Integrated Wealth Concepts LLC owned about 0.38% of NanoViricides worth $80,000 at the end of the most recent quarter. 10.30% of the stock is currently owned by institutional investors and hedge funds.
About NanoViricides
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Featured Articles
- Five stocks we like better than NanoViricides
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Stock Analyst Ratings and Canadian Analyst Ratings
- 3 Steel Stocks Soaring After Tariff Announcements
- Conference Calls and Individual Investors
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.